Assessment of The Clinical Course of Dyspnea in Acute Heart Failure Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01615926
Recruitment Status :
(Student related research project. Completion of allotted time.)
Acute heart failure (AHF) is defined as a gradual or rapid change in heart failure (HF) signs and symptoms, such as shortness of breath (also called dyspnea or breathlessness), leg swelling, fatigue, breathlessness with exertion, trouble sleeping flat at night, and weight gain resulting in a need for urgent therapy. AHF results in over 1 million hospitalizations every year, resulting in an enormous public health burden. Approximately 1/3rd of patients will either be re-hospitalized or die within three months, and the resultant financial costs are large. As such, improving outcomes for AHF patients is critically important. Shortness of breath is the most common reason why patients with AHF present to the ER. As such, understanding how severe this symptom is, how much it improves with current treatments is very important to both patients and physicians. The purpose of this study is to determine the degree to which your shortness of breath improves during the first few days of hospitalization and its association with how fast you are breathing.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Adult patients who present to the Emergency Department with Acute Heart Failure
Male or female ≥ 18 years of age
AHFS is the primary working diagnosis for ER management and treatment with planned admission
Have received IV diuretic therapy
Enrolled within 3 hours of initial diuretic dose
BNP level is ≤ 300 pg/mL (may be initially enrolled and then will be excluded for second assessment)
Transplant recipients of any kind
Fever > 101.5
Severe lung disease (required home O2 or daily oral steroids)
Any ACS event within last 30 days
Life expectancy less than 12 months for any reason
Current treatment for any malignancy of any kind
Cardiogenic shock and/or requiring IV inotropic therapy